Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06931626

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Small Cell Lung Cancer

Sponsor: Nerviano Medical Sciences

Updated 5 times since 2025 Last updated: Nov 11, 2025 Started: Aug 15, 2025 Primary completion: Oct 30, 2026 Completion: Feb 28, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Small Cell Lung Cancer and is currently actively recruiting participants. Nerviano Medical Sciences leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE1
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1
Sep 2025 — Nov 2025 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Aug 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE1
May 2025 — Aug 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nerviano Medical Sciences

Data source: Nerviano Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Nashville, United States